Popular Articles

More Camden, N.J., Residents Using Needle Exchange Programs
A pilot needle exchange program in Camden, N.J., - one of four in the state - "was off to a slow start" when it began 18 months ago, but "now, 976 drug users have registered with the program - more people than those at the other pilot sites in Atlantic City, Newark or Paterson," the Cherry Hill Courier-Post reports. "In Camden, 854 people are living with HIV/AIDS, the eighth-highest number among New Jersey municipalities, according to the latest data from the state Department of Health and Senior Services. About a third of them were infected by dirty needles," the Courier-Post reports. Bob Baxter, who oversees Newark"s program, said needle exchanges provide "the most immediate benefit at the cheapest cost," in reducing the spread of blood-borne diseases. "While there"s no way to count the number of people who are no longer sharing needles because of the program, organizers say they hope to see their success correlate to lowered communicable disease rates," the article states (Hirsch, 7/20).
generic viagra online
Couples To Rely On Male Contraceptive For New Trial, UK
Couples are being asked to replace their usual form of birth control with a new male contraceptive in a study to test its effectiveness.
News of the day
What Is a Nail Fungal Infection? What Causes Nail Fungus Infections?
Also known as onychomycosis and tinea unguium, nail fungal infections are the most common diseases of the nails, making up about 50% of nail abnormalities. Both fingernails and toenails are susceptible to the infection, which usually manifests as discoloration and thickening of the nail and crumbling edges. The condition most commonly occurs in toenails.
Health Insurance

Forsyth Medical Center Participating In Avastin Trial For New Glioblastoma Patients

The Derrick L. Davis Forsyth Regional Cancer Center at Forsyth Medical Center is participating in a national trial of the experimental drug Avastin to treat glioblastoma, a fast-growing tumor of the brain or spinal cord. Forsyth Regional Cancer Center (FRCC) is participating in the third phase of the trial, testing the effectiveness of Avastin in conjunction with standard chemotherapy and radiation treatments for patients newly diagnosed with glioblastoma. This phase of the trial will enroll 700 participants nationwide, and FRCC is one of the first sites in the country to participate. The trial is part of the hospital"s neurosciences program. "Avastin has been shown to be effective in treating various types of cancer, with a low risk of serious side effects, so our hope is that it will improve outcomes for patients with brain tumors when it is added to standard-of-care treatments," says Volker Stieber, M.D., a radiation oncologist at the FRCC. "Phase III is the highest level of research for a drug, so we are excited to be part of a study that could advance treatment for patients with this type of cancer." In May, the U.S. Food and Drug Administration approved the use of Avastin to treat glioblastomas that have not responded to other therapies based on results from two Phase II studies that showed Avastin reduced tumor size in some glioblastoma patients. The new study evaluates this drug in newly diagnosed, never-treated glioblastoma patients. Glioblastoma is the most common and most aggressive type of primary brain tumor in humans, accounting for about half of all primary brain tumor cases. Despite its prevalence, however, glioblastomas occur in only two to three cases per 100,000 people in North America and Europe. In Forsyth County, three out of four patients diagnosed with glioblastoma are diagnosed at Forsyth Medical Center. The FRCC is currently screening patients for enrollment in the clinical trial. Eligible patients may qualify if they are newly diagnosed adults able to undergo partial removal of their tumors. Once enrolled, participants will remain in the study for up to one year. Freda Springs Forsyth Medical Center


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):